{"disease":{"id":"high-risk-myelodysplastic-syndrome-mds","name":"high risk myelodysplastic syndrome mds"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06681363","title":"Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04358393","title":"A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT03940352","title":"HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03787498","title":"A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Opna Bio LLC","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}